Charles Schwab Investment Management Inc. Decreases Stock Holdings in Omeros Co. (NASDAQ:OMER)

Charles Schwab Investment Management Inc. lowered its position in Omeros Co. (NASDAQ:OMER) by 2.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 475,526 shares of the biopharmaceutical company’s stock after selling 9,509 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.82% of Omeros worth $4,698,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. US Bancorp DE purchased a new position in Omeros in the fourth quarter worth $81,000. New York State Common Retirement Fund boosted its position in shares of Omeros by 245.4% in the 4th quarter. New York State Common Retirement Fund now owns 17,313 shares of the biopharmaceutical company’s stock worth $171,000 after purchasing an additional 12,300 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Omeros during the 4th quarter worth $121,000. Stordahl Capital Management Inc. acquired a new position in Omeros during the 4th quarter valued at about $395,000. Finally, Seros Financial LLC purchased a new stake in Omeros in the fourth quarter valued at about $159,000. Institutional investors own 48.79% of the company’s stock.

Omeros Stock Performance

Shares of OMER stock opened at $9.16 on Wednesday. Omeros Co. has a fifty-two week low of $2.61 and a fifty-two week high of $13.60. The firm has a market capitalization of $530.82 million, a PE ratio of -3.97 and a beta of 2.03. The stock’s 50-day simple moving average is $8.72 and its 200-day simple moving average is $7.44.

Analysts Set New Price Targets

OMER has been the topic of a number of research analyst reports. StockNews.com lowered Omeros from a “hold” rating to a “sell” rating in a research note on Friday, March 21st. D. Boral Capital reissued a “buy” rating and set a $36.00 target price on shares of Omeros in a research report on Friday, March 21st. Finally, Needham & Company LLC restated a “hold” rating on shares of Omeros in a research note on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.50.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.